International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with &gt;30% blasts

Dombret, Hervé; F. Seymour, John; Butrym, Aleksandra; Wierzbowska, Agnieszka; Selleslag, Dominik; Ho Jang, Jun; Kumar, Rajat; D. Cavenagh, James; C. Schuh, Andre; Candoni, Anna; Récher, Christian; Sandhu, Irwindeep; Bernal del Castillo, Teresa; Kathrin Al‐Ali, Haifa; Martinelli, Giovanni; Falantes, José; Noppeney, Richard; M. Stone, Richard; D. Minden, Mark; McIntyre, Heidi; Songer, S.; M. Lucy, Lela; L. Beach, C.; Döhner, Hartmut

doi:10.1182/blood-2015-01-621664

Public

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

Published in Blood • May 19, 2015

Authors:

Hervé Dombret

John F. Seymour

Aleksandra Butrym

Abstract

This multicenter, randomized, open-label, phase 3 trial evaluated azacitidine efficacy and safety vs conventional care regimens (CCRs) in 488 patients age ≥65 years with newly diagnosed acute myeloid leukemia (AML) with >30% bone marrow blasts. Before randomization, a CCR (standard induction chemoth...

Subject

Azacitidine

Medicine

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!